ZTS - Zoetis Inc.

NYSE - NYSE Delayed Price. Currency in USD
123.07
-3.57 (-2.82%)
At close: 4:03PM EDT
Stock chart is not supported by your current browser
Previous Close126.64
Open126.58
Bid122.00 x 800
Ask126.85 x 1000
Day's Range122.42 - 127.49
52 Week Range78.90 - 128.41
Volume2,231,448
Avg. Volume2,018,910
Market Cap58.773B
Beta (3Y Monthly)0.67
PE Ratio (TTM)43.49
EPS (TTM)2.83
Earnings DateOct 30, 2019 - Nov 4, 2019
Forward Dividend & Yield0.66 (0.52%)
Ex-Dividend Date2019-07-18
1y Target Est129.73
Trade prices are not sourced from all markets
  • Bayer Sells Animal Health Division to Elanco: Now What?
    Zacks

    Bayer Sells Animal Health Division to Elanco: Now What?

    On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.

  • Barrons.com

    Elanco Stock Tumbles After It Announces a Deal to Acquire Bayer’s Animal-Health Business

    Elanco Animal Health is one of the largest companies in its field and it plans to get a lot bigger with the $7.6 billion acquisition of Bayer’s animal-health business.

  • Bloomberg

    Elanco to Buy Bayer’s Animal-Health Unit for $7.6 Billion

    (Bloomberg) -- Elanco Animal Health Inc. clinched the purchase of Bayer AG’s animal-health unit in a deal valued at $7.6 billion, creating one of the biggest stand-alone veterinary-medicine companies in the world.Elanco, which was spun out from drugmaker Eli Lilly & Co. last year, will finance the acquisition with a mix of cash and stock. German drug giant Bayer AG will receive $5.32 billion in cash and $2.3 billion in Elanco Animal Health common shares. The transaction is expected to close in mid-2020.“This will create the No. 2 animal-health company,” Elanco Chief Executive Officer Jeffrey Simmons said in an interview. “We see this as a nice complement. The pet owner, the veterinarian and the farmer win in this transaction.”Shares of Elanco have been under pressure since news of the potential transaction first surfaced earlier this summer. Bloomberg reported that the companies were close to a deal on Aug. 7.Elanco declined as much as 6.3% in New York trading on Tuesday. Bayer shares traded in Germany were down less than 0.1%.Elanco, based in Greenfield, Indiana, expects the deal to add to its adjusted earnings per share in the first full year after it closes. Buying the Bayer division will significantly bulk up its pet business at a time when the agricultural sector has turned more volatile. Last week, Elanco narrowed its sales guidance as a result of the outbreak of a deadly swine flu in Asia, which caused a decline in its farm unit.“With a larger, more diverse animal-health company, the percentage of the vulnerability will be less,” Simmons said, adding that he expects the current swine flu outbreak will eventually pass.Pfizer Inc.’s decision to spin out its animal-health business, Zoetis Inc., in 2013 has prodded other drugmakers to shed their veterinary units. The businesses are often stable, profitable operations whose fortunes are more tied to macroeconomic trends like rising global wealth and protein consumption, instead of risky bets on drug research.For Bayer, the sale adds to the resources it could draw from to pay potential costs for thousands of claims that Roundup, the weedkiller it gained in last year’s Monsanto acquisition, causes cancer. Bayer is in discussions on a possible settlement, but reaching a resolution could take months, people familiar with the matter have said.Simmons said Elanco won’t face any exposure to the Roundup suits.Bullish SectorZoetis, the former Pfizer unit, has seen its stock almost triple since it became an independent company. Elanco finished trading on Monday up 24% since its 2018 stock-market debut. Merck & Co. remains the only major pharmaceutical company that has held onto its animal-health unit, which generates about a 10th of its revenue.The deal would make Elanco the second-largest global animal-health business after Zoetis in terms of revenue, increasing its reach among farmers and pet owners. While it would be the new company’s biggest deal as an independent business, parent Eli Lilly bought Novartis AG’s animal-health unit in 2015 for $5.4 billion and combined the two firms’ assets.“Our top focus is now delivering our pipeline, bolt-ons, and other M&A is not needed,” Simmons said.Wall Street analysts have expressed reservations about the potential deal, saying that the Bayer business is unlikely to deliver a significant boost to Elanco’s growth.“Elanco is buying what I view as a flat-to-declining business that doesn’t innovate and has a high concentration risk,” Kevin Ellich, an analyst at Craig-Hallum Capital Group, said in an interview before the deal was announced. “The deal is dilutive to shareholders. At the end of the day, it’s just not that attractive. I don’t see how the stock goes up.”Simmons said he’s looking forward to setting the record straight with investors. “Now we’re able to respond to the marketplace: There’s been no change in our strategy, this is about growth and innovation,” he said.Elanco intends to work with regulators on potential antitrust issues, but sees the two portfolios as complementary.Goldman Sachs served as financial adviser to Elanco, while Paul, Weiss, Rifkind, Wharton & Garrison LLP and Hengeler Mueller were its legal counsel. Elanco’s board of directors was provided a fairness opinion by Duff & Phelps. Bank of America Merrill Lynch and Credit Suisse acted as financial advisers to Bayer, while Sullivan & Cromwell, PwC Legal and Linklaters served as its legal advisers.(Updates stock-price information in fifth paragraph)To contact the reporter on this story: Riley Griffin in New York at rgriffin42@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy Annett, Mark SchoifetFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • The Top Pharma Stocks for 2019
    Investopedia

    The Top Pharma Stocks for 2019

    Find out how the pharmaceutical industry is thriving, the new drugs that are coming to market, and the top pharmaceutical stocks for 2019.

  • Business Wire

    Zoetis to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

    Zoetis Inc. (ZTS) will participate in the Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, Sept. 10, 2019, in New York, N.Y. Glenn David, Executive Vice President and Chief Financial Officer, and Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, will represent the company and respond to questions from analysts. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses.

  • HKMPF or ZTS: Which Is the Better Value Stock Right Now?
    Zacks

    HKMPF or ZTS: Which Is the Better Value Stock Right Now?

    HKMPF vs. ZTS: Which Stock Is the Better Value Option?

  • Business Wire

    Zoetis Completes Acquisition of Platinum Performance, a Leading Nutrition-Focused Animal Health Business

    Zoetis Inc. (ZTS) today announced the completion of the acquisition of Platinum Performance, a privately-held nutrition-focused animal heath company, after fulfilling all closing requirements. The acquisition was first announced on July 22 and financial terms of the transaction are not being disclosed. “We are pleased to welcome the Platinum Performance team to Zoetis and together expand on the success of their high-quality, nutritional product formulas for horses, dogs and cats,” said Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy for Zoetis.

  • 3 Healthcare Stocks at All-Time Highs: Are They Buys?
    Motley Fool

    3 Healthcare Stocks at All-Time Highs: Are They Buys?

    They're flying high right now. But are these three healthcare stocks smart picks?

  • Should We Be Delighted With Zoetis Inc.'s (NYSE:ZTS) ROE Of 57%?
    Simply Wall St.

    Should We Be Delighted With Zoetis Inc.'s (NYSE:ZTS) ROE Of 57%?

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

  • Thomson Reuters StreetEvents

    Edited Transcript of ZTS earnings conference call or presentation 6-Aug-19 12:30pm GMT

    Q2 2019 Zoetis Inc Earnings Call

  • Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
    Zacks

    Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates

    Pacira (PCRX) rides high on both earnings and revenue beat in the second quarter of 2019. Moreover, Exparel drives year-over-year growth.

  • Has Zoetis (ZTS) Outpaced Other Medical Stocks This Year?
    Zacks

    Has Zoetis (ZTS) Outpaced Other Medical Stocks This Year?

    Is (ZTS) Outperforming Other Medical Stocks This Year?

  • Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?
    Zacks

    Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?

    Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • Zoetis (ZTS) Looks Good: Stock Adds 7.6% in Session
    Zacks

    Zoetis (ZTS) Looks Good: Stock Adds 7.6% in Session

    Zoetis (ZTS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

  • GuruFocus.com

    Wall Street Advances on Tuesday

    Marriott International declines on quarterly results Continue reading...

  • Animal-Health Stock Jumps To Record High As Spending On Fido Grows
    Investor's Business Daily

    Animal-Health Stock Jumps To Record High As Spending On Fido Grows

    Zoetis stock surged to a record high Tuesday after the animal-health company beat second-quarter forecasts and raised its 2019 guidance. Allergan also narrowly beat second-quarter estimates.

  • Zoetis Inc (ZTS) Q2 2019 Earnings Call Transcript
    Motley Fool

    Zoetis Inc (ZTS) Q2 2019 Earnings Call Transcript

    ZTS earnings call for the period ending June 30, 2019.

  • Zoetis Keeps Growing, but Headwinds Persist
    Motley Fool

    Zoetis Keeps Growing, but Headwinds Persist

    Spending is taking a bite out of the bottom line, and livestock products continue to perform poorly, but that didn't keep the animal health leader from increasing its outlook for the year.

  • Barrons.com

    Zoetis Stock Is Up as Pet Products Lift Revenue

    Shares of (ZTS) were up about 7% early Tuesday after the large animal-health company’s second-quarter results revealed strong growth in revenue from pet products. On an adjusted basis, the company (ticker: ZTS) earned 90 cents a share, up from 77 cents a year earlier. The pet business was a big source of growth for the company.

  • Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance
    Zacks

    Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance

    Zoetis (ZTS) beats on earnings and sales in the second quarter and also raises its 2019 outlook.

  • Which Pharmaceutical Stocks Are Outperforming All Other Stocks?
    Investor's Business Daily

    Which Pharmaceutical Stocks Are Outperforming All Other Stocks?

    The best pharmaceutical stocks to buy have commonalities: strong Composite Ratings and Relative Strength Ratings.

  • Zoetis (ZTS) Tops Q2 Earnings and Revenue Estimates
    Zacks

    Zoetis (ZTS) Tops Q2 Earnings and Revenue Estimates

    Zoetis (ZTS) delivered earnings and revenue surprises of 9.76% and 2.07%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Zoetis Reports Q2 Earnings Beat, Raises Guidance

    Zoetis (NYSE: ZTS ) reported second-quarter earnings of 90 cents per share, which beat the analyst consensus estimate of 82 cents by 9.76%. This is a 16.88% increase over earnings of 77 cents per share ...

  • Business Wire

    Zoetis Announces Second Quarter 2019 Results

    Zoetis $ZTS reports Q2'19 financial results.